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Melanoma cells express the platelet-activating factor receptor (PAFR) and, thus, respond to PAF, a bioactive lipid produced by
both tumour cells and those in the tumour microenvironment such as macrophages. Here, we show that treatment of a human
melanoma SKmel37 cell line with cisplatin led to increased expression of PAFR and its accumulation. In the presence of exogenous
PAF, melanoma cells were signiﬁcantly more resistant to cisplatin-induced cell death. Inhibition of PAFR-dependent signalling
pathways by a PAFR antagonist (WEB2086) showed chemosensitisation of melanoma cells in vitro. Nude mice were inoculated
with SKmel37 cells and treated with cisplatin and WEB2086. Animals treated with both agents showed signiﬁcantly decreased
tumourgrowthcomparedtothecontrolgroupandgroupstreatedwithonlyoneagent.PAFRaccumulation andsignallingarepart
of a prosurvival program of melanoma cells, therefore constituting a promising target for combination therapy for melanomas.
1.Introduction
Platelet-activating factor (PAF, 1-O-alkyl-2-acetyl-sn-glyc-
ero-3-phosphorylcholine) is associated with diverse phys-
iological functions [1–3]. It is produced from membrane
glycerophospholipids by enzymatic hydrolysis catalyzed by
phospholipase A2, which concomitantly generates arachi-
donic acid that is later converted to precursors of eicosanoids
[1, 4]. PAF is secreted by many diﬀerent cell types, including
endothelial, stromal, and inﬂammatory cells, as well as
platelets and keratinocytes. It has also been described to
be produced by many diﬀerent tumour cells [5–7]. PAF is
not stored in cells and its synthesis relies mainly on cell
activation, occurring in response to diﬀerent stimuli, such
as growth factors, PAF agonists, ultraviolet light irradiation,
and oxidative stress, including stress induced by chemother-
apy [1, 6].
PAFactsviaitsmembrane-associatedreceptorinrespon-
sive cells [4]. PAF receptor (PAFR) is a seven transmem-
brane-spanning G-protein coupled receptor expressed in
several cell types, such as endothelial and inﬂammatory
cells, and also in tumour cells. Engagement of PAFR induces
phosphatidylinositol turnover, a rise in intracellular calcium,
and activation of kinases and antiapoptotic pathways [8–
10]. The binding of PAF to its receptor results in the
transcription of several genes encoding cytokines such
as IL-6, -8, -10, TNF-α, and VEGF, as well as COX-2
and iNOS. It also elicits eicosanoid and PAF production.
Interestingly, diﬀerent angiogenic factors, such as VEGF
and FGF, induce PAF synthesis in a positive feedback loop
[1, 6, 11, 12].
The role of PAF/PAFR in tumours has been investigated
in recent years. PAF has been associated with early malignant
transformation in BRCA1-mutant epithelial ovarian cells2 Mediators of Inﬂammation
[13], while melanocytic tumorigenesis has been observed
in transgenic mice overexpressing PAFR [14]. In tumours,
PAF has also been described to negatively modulate the
local immune system, inhibiting Th1 responses and pro-
moting tumour growth [1, 11]. Intratumoural production
of PAF has been attributed to both tumour cells and
microenvironmental cells, such as inﬁltrating macrophages,
and has been shown to be responsible for potentiating
tumour growth, neoangiogenesis, and cell motility [12, 15].
The many eﬀects of PAF in tumours, such as increased
vascular permeability, induction of neoangiogenesis, and
activation of metalloproteinases, along with its systemic
eﬀects, including increased cell adhesion to endothelia, have
reinforced the concept that PAF promotes tumour metastasis
[1, 5].
Recent experiments have shown an important role of
PAF in chemotherapy, demonstrating that PAFR activation
can augment cytokine production induced by chemotherapy
through a mechanism dependent on NF-κB[ 16]. Despite
contrary reports [6], recent data have shown that PAFR
activation induces upregulation of antiapoptotic gene prod-
ucts, such as Bcl-2, thus attenuating the cytotoxic eﬀect of
chemotherapeutic agents [9]. In this scenario, speciﬁc PAFR
antagonists may have a potential eﬀect in blocking protective
tumour responses and potentiating chemotherapy [17–19].
Earlier experiments from our group have shown that
the PAFR antagonist WEB2170 inhibits tumour growth in a
murine melanoma model, improving overall survival when
combined with chemotherapy [20]. This led us to investigate
the role of PAFR in human melanoma cell lines and
evaluate the mechanisms of microenvironmental response
and possible inhibition of tumour growth in a combination
therapy with a similar PAFR antagonist, WEB2086.
2.MaterialsandMethods
2.1. SKmel37 Human Melanoma Cells. The human melano-
ma line SKmel37 was cultured in minimal essential medium
Eagle (MEM) (Gibco, Invitrogen, Carlsbad, CA, USA), pH
7.2 supplemented with 10% fetal bovine serum (Gibco,
Invitrogen,Carlsbad,CA,USA),intheabsenceofantibiotics,
at 37◦C and 5% CO2.
2.2. In Vitro Experiments with SKmel37. SKmel37 cells
were cultured in vitro and treated with cisplatin (con-
centrations of 2.5 and 5.0μM) and/or WEB2086 (5 and
20μg/mL) and/or PAF (3μg/mL, β-acetyl-γ-O-hexadecyl-
L-α-phosphatidylcholine, Sigma-Aldrich, St. Louis, MO,
USA). After treatment, the cells were washed twice with
phosphate-buﬀered saline (PBS) at room temperature (RT)
and removed with a cell scraper in a protein lysis buﬀer (1%
Triton X-100, 1% sodium deoxycholate deocolate, 150mM
NaCl, 1% sodium dodecyl sulphate (SDS), 10mM NaF,
50mM Tris-HCl2 μg/mL aprotinin, 1mM PMSF (phenyl-
methanesulphonyl ﬂuoride) and 1mM sodium orthovana-
date for protein extraction. Cells were then collected in a
PBS-EDTA and 0.25% trypsin solution (Gibco, Invitrogen,
Carlsbad, CA, USA) for ﬂow cytometric experiments.
2.3. Animals. Twelve-week-old female nude mice received
a subcutaneous inoculation of 1 × 106 SKmel37 human
melanoma cells in the right ﬂank. Animals were submitted to
all procedures in a laminar hood and housed in groups of 7
individualsinventilatedcages(Alesco,Campinas,SP,Brazil).
Animals were maintained in ventilated racks with sterilised
food and water ad libitum, in a 12/12h light/dark cycle. All
procedures were in accordance with the ethical principles
adopted by the Brazilian College of Animal Experimentation
and approved by the Ethical Committee for Animal Research
of the Faculdade de Medicina da Universidade de S˜ ao Paulo
(procedure approval number 0993/09).
2.4. Evaluation of Tumour Growth. SKmel37 cells (1 ×
106 cells) were injected subcutaneously in nude mice and
tumour growth was determined by measuring the diameter
of the solid tumour mass, from which the volume was esti-
mated using the formula for a spheroid: V = 0.52 × (largest
axis) × (smallest axis)2.
2.5. Treatments. Nude mice were divided into 4 groups
of 7 animals and received the following treatments: no
treatment (control group), only cisplatin, only WEB2086,
and cotreatment of cisplatin with WEB2086. The PAFR
antagonist WEB2086 (5mg/kg; Tocris, Ellisville, Missouri,
USA) was injected intraperitoneally (i.p.) seven days after
tumour implantation (when more than half of the animals
had palpable tumours) and repeated 14 and 21 days after
the implantation. Animals were treated concomitantly with
cisplatin (2mg/kg, Sigma-Aldrich, St. Louis, MO, USA). The
control groups received the same volume of the dilution
vehicle (PBS for cisplatin; PBS + DMSO at 0.3% for
WEB2086). Animals were sacriﬁced one day after the third
cycle of treatment (22 days after inoculation) in a carbon
dioxide (CO2) chamber in an increased CO2 degree machine
program until all animals were euthanised.
2.6. Human PAFR Gene Expression. RNA was isolated
using TRIzol reagents (Life-Technologies). For the real-
time reverse-transcriptase polymerase chain reaction (PCR),
cDNA was synthesized using the RevertAid First Strand
cDNASynthesisKit(FermentasLifeSciences,Ontario,USA),
according to the manufacturer’s instructions. PCR-master
mix (Power SyBr Green, Applied Biosystems, Warrington,
UK)containingthespeciﬁcprimerswerethenadded.hPAFR
sense primer GGGGACCCCCATCTGCCTCA and anti-
sense primer GCGGGCAAAGACCCACAGCA and GAPDH
sense primer GAGTCAACGGATTTGGTCGT and anti-sense
primer TTGATTTTGGAGGGATCTCG. Real-time PCR was
performed using a Stratagene Mx3005P QPCR Systems
(Santa Clara, CA, USA). Relative gene expression of hPAFR
and GAPDH were calculated by 2(−ΔΔC(T)).D a t aa r es h o w n
in fold increase related to untreated cells.
2.7. Western Blotting. Total protein extraction was carried
out after cells were homogenised in 1% Triton X-100,
1% sodium deoxycholate, 150mM NaCl, 1% SDS, 10mM
NaF, 50mM Tris-HCl, 2μg/mL aprotinin, 1mM PMSF, andMediators of Inﬂammation 3
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Figure 1: Cisplatin-treated SKmel37 cells accumulate PAFR. (a)
qPCR analysis of PAFR expression in SKmel37 cells exposed to
cisplatin for 6 and 24 hours, relatively to expression levels of
GAPDH. PAFR expression was signiﬁcantly increased in cells
treated with 5mM cisplatin after 6 hours, but not in any other
condition, as compared to the control (CTL, no treatment;
∗∗P <
0.01).(b)Westernblotanalysisofinvitrocisplatin-treatedSKmel37
cells using anti-PAFR and anti-β-actin antibodies. At 6h after
treatment, cells exposed to cisplatin did not reveal signiﬁcant
increase in PAFR protein expression, while at 24h, cells treated with
increasing concentrations of cisplatin presented an up to 2.6-fold
increase in PAFR levels.
1mMsodiumorthovanadate.Toremoveinsolublematerials,
centrifugation (13,000g centrifugation, 4◦Cf o r1 5m i n u t e s )
was performed. Protein concentration was determined using
the bicinchoninic acid method. Total protein extracts from
each sample were eletrophoretically separated in SDS-PAGE
and electroblotted onto a PVDF membrane according to
standard procedures. Membranes were blocked with PBS-
Tween containing 5% nonfat dry milk and then incubated
with an anti-PAF receptor polyclonal antibody (rabbit anti-
mouse PAFR, Cayman Chemical) and anti-β-actin mouse
monoclonal antibody (Sigma-Aldrich) in PBS-Tween con-
taining 1% BSA for 12h at 4◦C. Controls for reactivity of
anti-PAF receptor antibody included western blottings of
protein extracts from macrophages derived from wild-type
(positive control) and PAFR null mice (negative control).
Membranes were washed with PBS-Tween and incubated
with a speciﬁc horseradish peroxidase- (HRP-) labelled sec-
ondary antibody (Sigma-Aldrich, 1:5,000). Reactive bands
were detected with luminol and H2O2 using an image
capture system (Image Quant LAS 4000, GE Health care).
2.8. Flow Cytometry. After treatment, cells were ﬁxed in 70%
ethanol for at least 2h, washed twice in PBS (5min, 600×g),
and then incubated with 200μL of a propidium iodide
(PI) solution containing 20μg/mL of PI (Sigma, St. Louis,
MO, USA), 200μg/mL RNAse A (Invitrogen Biotechnology,
Carlsbad, CA, USA), and 0.1% Triton v/v in PBS. After
30min of incubation in the dark, data were acquired in a
FACSCALIBUR ﬂow cytometer (BD Biosciences, San Jose,
CA, USA). Samples were analysed using the Cell Quest Pro
software, and the results were expressed in the percentage
of hypodiploid cells and those in the G0/G1, S, and G2/M
phases.
2.9. Statistical Analyses. Data were analysed using one-
way ANOVA followed by Bonferroni post hoc tests using
GraphPad Prism 4.0 software. Diﬀerences were considered
signiﬁcant when P<0.05.
3. Results and Discussion
3.1. SKmel37 Cells In Vitro Express PAFR, and Treatment with
Cisplatin Induces Increased PAFR Expression. SKmel37 cells
were cultured in vitro and treated with cisplatin (2.5 and
5.0μM) for 6 and 24h. PAFR expression was evaluated by
qPCR and its accumulation analyzed by Western blotting
and ﬂow cytometric experiments. Control cells received no
treatment. However, when treated with cisplatin, SKmel37
cells had increased expression of PAFR (Figure 1), observed
both at the RNA level, upon 6h of cisplatin treatment, and at
the protein level, after 24h of treatment (Figures 1(a) and
1(b)). Speciﬁcity of the polyclonal antibody to PAFR was
ascertained by lack of speciﬁc labeling in western blottings of
protein extracts of macrophages derived from PAFR knock-
out mice (data not shown). These results show that PAFR
is present in SKmel37 cells, and its expression is induced by
exposure to the chemotherapeutic agent cisplatin in a dose-
dependent manner (up to 5μM). Increase in the expression
of the PAFR within six hours of treatment suggests de novo
expressionofthePAFRgeneandsubsequentaccumulationof
its product along the ﬁrst 24 hours of treatment. It has been
shown that cisplatin induces endoplasmic reticulum stress
[21], a switch between an autophagic prosurvival response
and an apoptotic response. Apoptosis tends to occur at
later time points (such as 24 hours). The cellular response
to cisplatin may explain the drop of mRNA levels for the
PAFR gene after 24 hours of cisplatin exposure, as observed
in Figure 1(a). These data strengthen the proposed role of
PAFR as part of a protective response to cell damage and
cell death [22], such as that caused by chemotherapy, and
indicate that the SKmel37 cell line might be susceptible to
the eﬀects of blocking the PAFR pathway by inhibiting the
tumour cell response to stress and subsequently enhancing
chemotherapy eﬃcacy.4 Mediators of Inﬂammation
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Figure 2: PAF protects SKmel 37 cells from cisplatin-induced cell
death in vitro. (a) Cell death was measured as the percentage of
hypodiploid cells (in total cell population) at each condition. (b)
Cell cycle analysis of the live cell population in each condition. CIS:
cisplatin; WEB: WEB2086.
3.2. PAF Protects SKmel37 Cells from Cell Death Induced
by Cisplatin In Vitro, and the PAFR Antagonist WEB2086
Enhances Cisplatin-Induced Cell Death in the Presence of
PAF. SKmel37 cells were cultivated in vitro and treated with
cisplatin (5μM) and WEB2086 (5μg/mL) for 24h, in the
presenceorabsenceofPAF(3μmol/L,basedonexperimental
delineation in Seo et al. [9]). WEB2086 was initially added to
the culture medium, and after 30 minutes, cisplatin and/or
PAF were added. After 24 hours, cells were harvested with
trypsin. Distribution of cells within diﬀerent phases of the
cell cycle and cell death were assessed by propidium iodide
staining. Data were analysed with one-way ANOVA and
Bonferroni posttests.
In the absence of PAF in the culture medium, WEB2086
had no eﬀect on cell death, while only cisplatin caused a
signiﬁcant increase in cell mortality that was not aﬀected
by WEB2086 (Figure 2(a)). When PAF was added to the
cell culture, there was a signiﬁcant decrease in cell death,
indicating that PAF has a protective eﬀect on tumour cells.
However, there was a clear increase in cell death when
cells were exposed to cisplatin and WEB2086, compared to
cisplatin alone, although this was not statistically signiﬁcant.
The presence of PAF in the culture medium more closely
resembles the in vivo condition (in which PAF is present
in the microenvironment, produced by tumour and/or
microenvironmental cells). These results further support
the idea that PAFR-dependent pathways may be involved
in a protective response to cell damage and when blocked,
cell death induced by chemotherapeutic treatment increases.
Indeed, cells treated with cisplatin in the presence of PAF
showed a signiﬁcant decrease in cell death, compared to cells
treated with cisplatin in the absence of PAF, thus suggesting
that PAF may protect SKmel37 cells from cisplatin-induced
death. This led us to investigate the potential eﬀect of PAFR
antagonism in an in vivo model subjected to chemotherapy.
Cell cycle analysis demonstrated the eﬀectiveness of
treatment with cisplatin, showing an accumulation of cells
in S/G2/M (Figure 2(b)). Interestingly, exposure to PAF or
WEB2086 alone did not cause signiﬁcant changes in the cell
cycle, as observed in normal nonmalignant retinal cells, in
which PAF causes an arrest of the cell cycle at the S/G2
transition [23].
3.3. Combination Therapy with Cisplatin and WEB2086
in Melanoma-Bearing Mice Slows Tumour Progression and
Increases Tumour Regression. SKmel37 cells (1 × 106)w e r e
injected subcutaneously into nude mice, and tumours were
measured daily with a caliper. Tumour volume was cal-
culated by the formula: maximum diameter × (minimum
diameter)2 × 0.52. Cisplatin (2mg/kg) and/or WEB2086
(5mg/kg) were injected intraperitoneally every 7 days after
the tumour cell injection, for a total of 3 cycles of treatment.
Animals were sacriﬁced and had their tumours excised
one day after the last cycle of treatment. The growth
curves (Figure 3(a)) showed a slight decrease in tumour
volume in mice treated with either cisplatin or WEB2086,
in comparison to the control group; however, the most
important ﬁnding was a signiﬁcant inhibition of tumour
growth in the group submitted to the combination therapy
(cisplatin and WEB2086). This group showed the highest
percentage of complete tumour regression (accounted as
tumours that reached a minimum size of 2mm × 2mm
and afterwards, during the course of therapy, disappeared
completely, not being detected macroscopically through
inspection/palpation or during animal dissection, as shown
in Figure 3(b)). These data suggest that combination therapyMediators of Inﬂammation 5
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Figure 3: Combination therapy using cisplatin and the antagonist of PAFR is more eﬃcient than either therapy alone (a) Average tumour
volume in each experimental group (±SEM) measured daily. (b) Percentage of complete tumour regression in each experimental condition.
was eﬀective not only in slowing tumour growth, but also in
reducing and possibly eliminating tumours.
These results show that part of the antitumour eﬀect
of WEB2086 may result from a direct eﬀect on tumour
cells, potentiated by the increased expression of PAFR via
cisplatin,thusmakingtumourcellsmoresusceptibletoPAFR
antagonism and also supporting the presence of PAF in the
tumour microenvironment. Interestingly, the decrease in cell
proliferationobservedwithcotreatmentinthis invivomodel
was signiﬁcant, diﬀerent to what was observed in the in
vitro model. This suggests that tumour growth inhibition
and cell death are not only the consequences of direct PAFR
antagonism in tumour cells, but also probably results from
the eﬀect of PAFR antagonism in other microenvironmental
cell types, such as endothelial cells (especially in the context
of neoangiogenesis inhibition) and inﬁltrating inﬂammatory
cells.
4. Conclusions andPerspectives
The observation that chemotherapy caused an increase in
PAFR expression in human melanoma SKmel37 cells indi-
cated the possible participation of PAFR in tumour response
m e c h a n i s m s ,s u c ha ss t r e s sr e s p o n s e sc a u s e db yc h e m o t h e r a -
peutic agents. Here we provided empirical evidence that the
PAFR pathway is involved in a protective response to cell
damage and its blockage favors chemotherapy-induced cell
death.
There is now increasing evidence for activation of
cytosolic calcium-independent phospholipase A2 (iPLA2) in
the microenvironment of tumors subjected to therapy, for
example, radiotherapy, in a caspase-3-dependent manner
[24]. Activation of iPLA2 led to increased production
of arachidonic acid and subsequent PGE2 production.
At the same time, iPLA2 activity favors accumulation of the
PAF precursor. We had previously shown that presence of
apoptotic cells within the tumor microenvironment favored
tumor growth [25], a process known as tumor repopulation
[24]. Our results suggest that activation of PAFR pathways
may support tumor survival and therefore tumor repopu-
lation in melanomas. These results are of potential interest
as they widen the ﬁeld of investigation into the roles of
PAFR and also support the concept that PAFR antagonists
may be useful for adjuvant therapy, improving the eﬃcacy of
chemotherapy.
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